ESMO 2019 | Erdafitinib for bladder cancer: more to come following FDA approval

Erdafitinib, an FGFR3 inhibitor, was approved by the FDA in April 2019 for the treatment of FGFR3+ metastatic urothelial carcinoma patients. Here Arlene Siefker-Radtke, MD, from the University of Texas MD Anderson Cancer Center, Houston, TX, discusses what’s next for this agent, including its future in Europe and the THOR trial (NCT03390504).